Free Trial
Reni J. Benjamin

Reni J. Benjamin Analyst Performance

Managing Director/ Biotechnology Equity Research at Citizens Capital Markets and Advisory at Citizens Jmp

Reni J. Benjamin is a stock analyst at Citizens Jmp focused in the medical sector, covering 18 publicly traded companies. Over the past year, Reni J. Benjamin has issued 26 stock ratings, including buy and hold recommendations. While full access to Reni J. Benjamin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Reni J. Benjamin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
26 Last 0 Years
Buy Recommendations
92.31% 24 Buy Ratings
Companies Covered
18 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy92.3%24 ratings
Hold7.7%2 ratings
Sell0.0%0 ratings

Out of 26 total stock ratings issued by Reni J. Benjamin at Citizens Jmp, the majority (92.3%) have been Buy recommendations, followed by 7.7% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
18 companies

Reni J. Benjamin, an analyst at Citizens Jmp, currently covers 18 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
16 companies
88.9%
Manufacturing
2 companies
11.1%

Reni J. Benjamin of Citizens Jmp specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
12 companies
66.7%
MED - DRUGS
4 companies
22.2%
PHARMACEUTICAL PREPARATIONS
2 companies
11.1%

Reni J. Benjamin's Ratings History at Citizens Jmp

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
4/28/2026Reiterated Rating$1.97$10.00Market Outperform
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
4/23/2026Boost Price Target$35.32$41.00Market Outperform
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
4/17/2026Boost Price Target$30.28$35.00Market Outperform
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
4/16/2026Initiated Coverage$3.90$8.00Market Outperform
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
4/14/2026Boost Price Target$3.04$8.00Market Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3/31/2026Reiterated Rating$19.04$31.00Market Outperform
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
3/27/2026Reiterated Rating$9.02$23.00Market Outperform
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
3/9/2026Initiated Coverage$22.46$34.00Market Outperform
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
3/3/2026Upgrade$3.79$5.00Market Outperform
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2/25/2026Upgrade$3.78$5.00Outperform
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2/23/2026Initiated Coverage$2.79$10.00Market Outperform
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2/17/2026Initiated Coverage$2.64$6.00Market Outperform
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
1/30/2026Reiterated Rating$15.40$40.00Market Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
1/29/2026Initiated Coverage$16.59$31.00Market Perform
Zymeworks Inc. stock logo
ZYME
Zymeworks
12/3/2025Initiated Coverage$25.10$32.00Market Outperform
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
11/7/2025Boost Price Target$332.36$396.00Market Outperform
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
10/30/2025Boost Price Target$5.37$8.00Market Outperform
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
10/20/2025Reiterated Rating$20.31$40.00Market Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
10/20/2025Reiterated Rating$9.82$24.00Market Outperform
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
9/3/2025Reiterated Rating$24.15$40.00Market Outperform
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
8/22/2025Reiterated Rating$24.16Market Perform
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
8/21/2025Lower Price Target$1.24$3.00Market Outperform
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
8/19/2025Reiterated Rating$26.29$40.00Market Outperform
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
8/18/2025Lower Price Target$0.87$3.00Market Outperform
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
8/12/2025Lower Price Target$7.46$10.00Market Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
8/11/2025Lower Price Target$5.54$24.00Market Outperform